Latest Regulatory Milestones News

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.

Infomedia Limited has received crucial regulatory clearance from the German Federal Ministry for Economic Affairs and Energy for its proposed acquisition by McQueen BidCo, advancing the scheme of arrangement. The company’s board continues to recommend shareholder approval amid remaining conditions.

PYC Therapeutics has reported encouraging pre-clinical results for its RNA therapy candidate PYC-002 targeting Phelan-McDermid Syndrome, supporting plans to enter human trials in 2026. The data demonstrate safety, brain distribution, and gene expression restoration in key disease regions.

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.

Centaurus Metals has secured the final mining lease for its Jaguar Nickel Project in Brazil, clearing a major regulatory hurdle and moving closer to a Final Investment Decision and project development.

Artrya Limited has successfully navigated a key FDA Q-Submission meeting, receiving clear guidance on the regulatory pathway for its Salix Coronary Flow module, with a 510(k) submission planned by year-end.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Battery Age Minerals has received initial drilling approval for its maiden program at the El Aguila Gold-Silver Project in Argentina, setting the stage for resource definition and exploration growth in a prolific mining region.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

Alligator Energy has begun construction of its Samphire Project Field Recovery Trial near Whyalla, marking a key step towards uranium production amid a strengthening market.

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

Macro Metals Limited confirms key permitting milestones and advances offtake negotiations for its Extension Iron Ore Project, targeting construction readiness by late 2026.